Program
LSD1 Inhibitor EXS74539
Its studies are mostly in Small Cell Lung Carcinoma, led by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals.
Furthest: phase 1, since Mar 27, 20261 company-led study, 1 open or runningNext primary completion: Mar 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals | 11 open or running | phase 1since Mar 27, 2026 | Mar 27, 2026 | Mar 2029phase 1 · NCT07517198 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 27, 2026First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT07517198 · 40 planned · United States
Ahead
- Mar 2029Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT07517198
TargetBeta
KDM1A →read by rule
“An orally bioavailable reversible and central nervous system (CNS) penetrant inhibitor of lysine-specific demethylase 1 (LSD1; KDM1A), ”NCIt, by rule
Other programs on KDM1A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| bomedemstat | Merck | phase 3 | 11 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07517198Small Cell Lung Carcinoma · United States | 1 | Recruiting | Mar 2029 | 40 |
How it is read
Names in the registry
- “EXS74539”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.